Melanoma, Experimental

"Melanoma, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

Descriptor ID	D008546
MeSH Number(s)	C04.557.465.625.650.510.525 C04.557.580.625.650.510.525 C04.557.665.510.525 C04.619.600 E05.598.500.496.937
Concept/Terms	Melanoma, Experimental Melanoma, Experimental Melanomas, Experimental Experimental Melanoma Experimental Melanomas Melanoma, Harding-Passey Melanoma, Harding-Passey Harding-Passey Melanoma Melanoma, Harding Passey Harding Passey Melanoma Melanoma, B16 Melanoma, B16 B16 Melanomas Melanomas, B16 B16 Melanoma Melanoma, Cloudman S91 Melanoma, Cloudman S91 Cloudman S91 Melanoma S91 Melanoma, Cloudman

Below are MeSH descriptors whose meaning is more general than "Melanoma, Experimental".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Germ Cell and Embryonal [C04.557.465]
Neuroectodermal Tumors [C04.557.465.625]
Neuroendocrine Tumors [C04.557.465.625.650]
Melanoma [C04.557.465.625.650.510]
Melanoma, Experimental [C04.557.465.625.650.510.525]
Neoplasms, Nerve Tissue [C04.557.580]
Neuroectodermal Tumors [C04.557.580.625]
Neuroendocrine Tumors [C04.557.580.625.650]
Melanoma [C04.557.580.625.650.510]
Melanoma, Experimental [C04.557.580.625.650.510.525]
Nevi and Melanomas [C04.557.665]
Melanoma [C04.557.665.510]
Melanoma, Experimental [C04.557.665.510.525]
Neoplasms, Experimental [C04.619]
Melanoma, Experimental [C04.619.600]
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Models, Animal [E05.598]
Disease Models, Animal [E05.598.500]
Neoplasms, Experimental [E05.598.500.496]
Melanoma, Experimental [E05.598.500.496.937]

Below are MeSH descriptors whose meaning is related to "Melanoma, Experimental".

Below are MeSH descriptors whose meaning is more specific than "Melanoma, Experimental".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Melanoma, Experimental" by people in this website by year, and whether "Melanoma, Experimental" was a major or minor topic of these publications.

Bar chart showing 48 publications over 21 distinct years, with a maximum of 6 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	1	0	1
1998	1	0	1
1999	0	2	2
2001	1	0	1
2004	0	1	1
2006	0	2	2
2007	2	1	3
2008	1	1	2
2009	2	0	2
2010	1	2	3
2011	1	0	1
2012	0	3	3
2013	1	0	1
2014	2	1	3
2015	2	1	3
2016	1	1	2
2017	4	0	4
2019	4	2	6
2020	2	0	2
2021	2	2	4

Below are the most recent publications written about "Melanoma, Experimental" by people in Profiles.

Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, Salek-Ardakani S. Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties. J Immunother Cancer. 2021 12; 9(12).

View in: PubMed
Iwanowycz S, Ngoi S, Li Y, Hill M, Koivisto C, Parrish M, Guo B, Li Z, Liu B. Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors. JCI Insight. 2021 09 08; 6(17).

View in: PubMed
Ou J, Tian H, Wu J, Gao J, Jiang J, Liu K, Wang S, Wang F, Tong F, Ye Y, Liu L, Chen B, Ma X, Chen X, Peng F, Tu Y. MnO2-Based Nanomotors with Active Fenton-like Mn2+ Delivery for Enhanced Chemodynamic Therapy. ACS Appl Mater Interfaces. 2021 Aug 18; 13(32):38050-38060.

View in: PubMed
Kauroo S, Govinden-Soulange J, Ranghoo-Sanmukhiya VM, Miranda K, Cotham WE, Walla MD, Nagarkatti M, Nagarkatti P. Extracts of select endemic plants from the Republic of Mauritius exhibiting anti-cancer and immunomodulatory properties. Sci Rep. 2021 02 19; 11(1):4272.

View in: PubMed
Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, de Mingo Pulido A, Mandula J, Zhang S, Thevenot P, Biswas S, Abdalla SK, Costich TL, Hänggi K, Anadon CM, Flores ER, Haura EB, Mehrotra S, Pilon-Thomas S, Ruffell B, Munn DH, Cubillos-Ruiz JR, Conejo-Garcia JR, Rodriguez PC. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020 04 14; 52(4):668-682.e7.

View in: PubMed
Lopes JE, Fisher JL, Flick HL, Wang C, Sun L, Ernstoff MS, Alvarez JC, Losey HC. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 04; 8(1).

View in: PubMed
Hurst KE, Lawrence KA, Reyes Angeles L, Ye Z, Zhang J, Townsend DM, Dolloff N, Thaxton JE. Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors. Cells. 2019 11 26; 8(12).

View in: PubMed
Yoshida A, Bu Y, Qie S, Wrangle J, Camp ER, Hazard ES, Hardiman G, de Leeuw R, Knudsen KE, Diehl JA. SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv. 2019 09; 5(9):eaax6352.

View in: PubMed
Chakraborty P, Vaena SG, Thyagarajan K, Chatterjee S, Al-Khami A, Selvam SP, Nguyen H, Kang I, Wyatt MW, Baliga U, Hedley Z, Ngang RN, Guo B, Beeson GC, Husain S, Paulos CM, Beeson CC, Zilliox MJ, Hill EG, Mehrotra M, Yu XZ, Ogretmen B, Mehrotra S. Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. Cell Rep. 2019 08 13; 28(7):1879-1893.e7.

View in: PubMed
Fang L, Zhao F, Iwanowycz S, Wang J, Yin S, Wang Y, Fan D. Anticancer activity of emodin is associated with downregulation of CD155. Int Immunopharmacol. 2019 Oct; 75:105763.

View in: PubMed

People

Explore

Similar Concepts

Top Journals